Cancer Supportive Care (CSC) is a field of increasing relevance for both oncology patients and clinical research. CSC is the prevention and management of the adverse effects of cancer and its treatment. This includes management of physical and psychological symptoms and side effects across the continuum of the cancer experience from diagnosis through anticancer treatment to post-treatment care. Today, CSC is fully integrated with anticancer treatment, and significantly concurs to increase quality, and partly, expectancy of life in patients, especially addressing the most dreaded consequences and complications, including nausea, emesis, malnutrition, pain, and psychological impact.

Helsinn Group is very much involved in the effort and contribution to the development of this discipline with either new medical compounds targeted at controlling those consequences and scientific and education projects aimed at increasing possibilities of cooperation, interaction and discussion among clinicians and researchers in the international setting.

Helsinn's Products Under Development in Cancer Supportive Care

 Helsinn's Commercialized Products in Cancer Supportive Care 

 Helsinn's Nutritional Supplements 

Palonosetron

Gelclair

Netupitant - Palonosetron Fixed Dose Combination

Anamorelin

ElsiglutideDaxibeQOL